Silencing human genetic diseases with oligonucleotide-based therapies (original) (raw)

References

• Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75–86
  Article PubMed CAS Google Scholar
• Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12:907–914
  Article PubMed CAS Google Scholar
• Abifadel M, Rabes JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C (2009) Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 30:520–529
  Article PubMed CAS Google Scholar
• Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP (2012) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19(Suppl 1):43–44
  Article PubMed CAS Google Scholar
• Ando Y, Ueda M (2012) Diagnosis and therapeutic approaches to transthyretin amyloidosis. Curr Med Chem 19:2312–2323
  Article PubMed CAS Google Scholar
• Andrade C (1952) A peculiar form of peripheral neuropathy: familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408–427
  Article PubMed CAS Google Scholar
• Arechavala-Gomeza V, Kinali M, Feng L, Guglieri M, Edge G, Main M, Hunt D, Lehovsky J, Straub V, Bushby K, Sewry CA, Morgan JE, Muntoni F (2010) Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 20:295–301
  Article PubMed Google Scholar
• Berntorp E, Gomperts E, Hoots K, Wong WY (2006) The next generation of hemophilia treatment specialists. Semin Thromb Hemost 32(Suppl 2):39–42
  Article PubMed Google Scholar
• Boyle MP (2007) Adult cystic fibrosis. JAMA 298:1787–1793
  Article PubMed CAS Google Scholar
• Brautbar A, Ballantyne CM (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol 8:253–265
  Article PubMed CAS Google Scholar
• Brouwer JR, Willemsen R, Oostra BA (2009) Microsatellite repeat instability and neurological disease. BioEssays 31:71–83
  Article PubMed CAS Google Scholar
• Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and future prospects. Chem Biol 19:60–71
  Article PubMed CAS Google Scholar
• Chambers LA, Rollins BM, Tarran R (2007) Liquid movement across the surface epithelium of large airways. Respir Physiol Neurobiol 159:256–270
  Article PubMed CAS Google Scholar
• Charlton-Menys V, Durrington PN (2008) Human cholesterol metabolism and therapeutic molecules. Exp Physiol 93:27–42
  PubMed CAS Google Scholar
• Chekulaeva M, Filipowicz W (2009) Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21:452–460
  Article PubMed CAS Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264–1272
  Article PubMed CAS Google Scholar
• Collawn JF, Lazrak A, Bebok Z, Matalon S (2012) The CFTR and ENaC debate: how important is ENaC in CF lung disease? Am J Physiol Lung Cell Mol Physiol 302:L1141–L1146
  Article PubMed CAS Google Scholar
• Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136:777–793
  Article PubMed CAS Google Scholar
• Crooke ST (2004) Progress in antisense technology. Annu Rev Med 55:61–95
  Article PubMed CAS Google Scholar
• Davidson BL, McCray PB Jr (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12:329–340
  Article PubMed CAS Google Scholar
• Day JW, Ranum LP (2005) Genetics and molecular pathogenesis of the myotonic dystrophies. Curr Neurol Neurosci Rep 5:55–59
  Article PubMed CAS Google Scholar
• Dedoussis GV (2007) Apolipoprotein polymorphisms and familial hypercholesterolemia. Pharmacogenomics 8:1179–1189
  Article PubMed CAS Google Scholar
• DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, Yoder J, Reeves P, Pandey RK, Rajeev KG, Manoharan M, Sah DW, Zamore PD, Aronin N (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104:17204–17209
  Article PubMed CAS Google Scholar
• Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G (1998) Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7:1083–1090
  Article PubMed CAS Google Scholar
• Dykxhoorn DM, Schlehuber LD, London IM, Lieberman J (2006) Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci USA 103:5953–5958
  Article PubMed CAS Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001a) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498
  Article PubMed CAS Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T (2001b) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15:188–200
  Article PubMed CAS Google Scholar
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811
  Article PubMed CAS Google Scholar
• Gagnon KT (2010) HD therapeutics—CHDI fifth annual conference. IDrugs 13:219–223
  PubMed Google Scholar
• Goyenvalle A, Seto JT, Davies KE, Chamberlain J (2011) Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20:R69–R78
  Article PubMed CAS Google Scholar
• Haddley K (2011) Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia. Drugs Today (Barc) 47:891–901
  CAS Google Scholar
• Harper SQ (2009) Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 66:933–938
  Article PubMed Google Scholar
• Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci USA 102:5820–5825
  Article PubMed CAS Google Scholar
• Hickerson RP, Smith FJ, McLean WH, Landthaler M, Leube RE, Kaspar RL (2006) SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann NY Acad Sci 1082:56–61
  Article PubMed CAS Google Scholar
• Hickerson RP, Flores MA, Leake D, Lara MF, Contag CH, Leachman SA, Kaspar RL (2011) Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model. J Invest Dermatol 131:1037–1044
  Article PubMed CAS Google Scholar
• Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919–928
  Article PubMed CAS Google Scholar
• Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B (2000) Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 97:9618–9623
  Article PubMed CAS Google Scholar
• Horton JD, Cohen JC, Hobbs HH (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32:71–77
  Article PubMed CAS Google Scholar
• Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR (2008) Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82:834–848
  Article PubMed CAS Google Scholar
• Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C, Krishna G, Davies JE, Ttofi E, Underwood BR, Rubinsztein DC (2008) Huntington’s disease: from pathology and genetics to potential therapies. Biochem J 412:191–209
  Article PubMed CAS Google Scholar
• Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ (1990) Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31:1337–1349
  PubMed CAS Google Scholar
• Jabs DA, Griffiths PD (2002) Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Ophthalmol 133:552–556
  Article PubMed CAS Google Scholar
• Kaspar RL (2005) Challenges in developing therapies for rare diseases including pachyonychia congenita. J Investig Dermatol Symp Proc 10:62–66
  Article PubMed Google Scholar
• Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918–928
  Article PubMed CAS Google Scholar
• Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Muller CR, Lindlof M, Kaariainen H et al (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498–506
  PubMed CAS Google Scholar
• Kubodera T, Yamada H, Anzai M, Ohira S, Yokota S, Hirai Y, Mochizuki H, Shimada T, Mitani T, Mizusawa H, Yokota T (2010) In vivo application of an RNAi strategy for the selective suppression of a mutant allele. Hum Gene Ther 22:27–34
  Article Google Scholar
• Lara MF, Gonzalez-Gonzalez E, Speaker TJ, Hickerson RP, Leake D, Milstone LM, Contag CH, Kaspar RL (2012) Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. Hum Gene Ther 23:816–823
  Article PubMed CAS Google Scholar
• Leachman SA, Hickerson RP, Hull PR, Smith FJ, Milstone LM, Lane EB, Bale SJ, Roop DR, McLean WH, Kaspar RL (2008) Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51:151–157
  Article PubMed CAS Google Scholar
• Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 18:442–446
  Article PubMed CAS Google Scholar
• Lopez-Fraga M, Martinez T, Jimenez A (2009) RNA interference technologies and therapeutics: from basic research to products. BioDrugs 23:305–332
  Article PubMed CAS Google Scholar
• Martinez T, Wright N, Pañeda C, Jimenez A, Lopez-Fraga M (2011) RNA interference-based therapeutics: harnessing the powers of nature In: Rundfeldt C (ed) Drug development: a case study based insight into modern strategies. InTech, pp 265–312
• Maxwell MM, Pasinelli P, Kazantsev AG, Brown RH Jr (2004) RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells. Proc Natl Acad Sci USA 101:3178–3183
  Article PubMed CAS Google Scholar
• McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagener G, Chasan-Taber S (2012) Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE 7:e49006
  Article PubMed CAS Google Scholar
• Mulders SA, van Engelen BG, Wieringa B, Wansink DG (2010) Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function. Hum Mol Genet 19:R90–R97
  Article PubMed CAS Google Scholar
• Nguyen J, Szoka FC (2012) Nucleic acid delivery: the missing pieces of the puzzle? Acc Chem Res 45:1153–1162
  Article PubMed CAS Google Scholar
• Pañeda C, Martinez T, Wright N, Jimenez A (2012) Recent advances in ocular nucleic-based therapies: the silent era. In: Adio A (ed) Ocular diseases. InTech, pp 157–185
• Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11:59–67
  Article PubMed CAS Google Scholar
• Perkel JMPD (2012) RNAi therapeutics: the teenage years. Biotechniques 52:355–357
  PubMed CAS Google Scholar
• Persidis A (1999) Antisense therapeutics. Nat Biotechnol 17:403–404
  Article PubMed CAS Google Scholar
• Phillips MI (2005) Antisense therapeutics: a promise waiting to be fulfilled. Methods Mol Med 106:3–10
  PubMed CAS Google Scholar
• Phillips W, Shannon KM, Barker RA (2008) The current clinical management of Huntington’s disease. Mov Disord 23:1491–1504
  Article PubMed Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11:423–428
  Article PubMed CAS Google Scholar
• Rettig GR, Behlke MA (2011) Progress toward in vivo use of siRNAs-II. Mol Ther 20:483–512
  Article PubMed Google Scholar
• Rigo F, Hua Y, Krainer AR, Bennett CF (2012) Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol 199:21–25
  Article PubMed CAS Google Scholar
• Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344:1688–1700
  Article PubMed CAS Google Scholar
• Samakoglu S, Lisowski L, Budak-Alpdogan T, Usachenko Y, Acuto S, Di Marzo R, Maggio A, Zhu P, Tisdale JF, Riviere I, Sadelain M (2006) A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol 24:89–94
  Article PubMed CAS Google Scholar
• Schlosser K, Li Y (2009) Biologically inspired synthetic enzymes made from DNA. Chem Biol 16:311–322
  Article PubMed CAS Google Scholar
• Schubert S, Kurreck J (2004) Ribozyme- and deoxyribozyme-strategies for medical applications. Curr Drug Targets 5:667–681
  Article PubMed CAS Google Scholar
• Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, Prat A (2008) The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 40:1111–1125
  Article PubMed CAS Google Scholar
• Shen TJ, Rogers H, Yu X, Lin F, Noguchi CT, Ho C (2007) Modification of globin gene expression by RNA targeting strategies. Exp Hematol 35:1209–1218
  Article PubMed Google Scholar
• Singh NN, Shishimorova M, Cao LC, Gangwani L, Singh RN (2009) A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol 6:341–350
  Article PubMed CAS Google Scholar
• Sjouke B, Kusters DM, Kastelein JJ, Hovingh GK (2011) Familial hypercholesterolemia: present and future management. Curr Cardiol Rep 13:527–536
  Article PubMed CAS Google Scholar
• Smith FJ, Liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P, Joval I, van Steensel MA, Bjorck E, Callif-Daley F, Pals G, Collins P, Leachman SA, Munro CS, McLean WH (2005) The genetic basis of pachyonychia congenita. J Investig Dermatol Symp Proc 10:21–30
  Article PubMed CAS Google Scholar
• Solis AS, Shariat N, Patton JG (2008) Splicing fidelity, enhancers, and disease. Front Biosci 13:1926–1942
  Article PubMed CAS Google Scholar
• Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M (2012) Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126:2283–2292
  Article PubMed CAS Google Scholar
• Stoller JK, Aboussouan LS (2012) A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 185:246–259
  Article PubMed CAS Google Scholar
• Sumner CJ (2006) Therapeutics development for spinal muscular atrophy. NeuroRx 3:235–245
  Article PubMed CAS Google Scholar
• Tomita N, Morishita R, Tomita T, Ogihara T (2002) Potential therapeutic applications of decoy oligonucleotides. Curr Opin Mol Ther 4:166–170
  PubMed CAS Google Scholar
• Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA (1999) Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 13:3191–3197
  Article PubMed CAS Google Scholar
• van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677–2686
  Article PubMed Google Scholar
• Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA, Zinder N, Levine AJ, Roberts RJ, Simon M, Slayman C, Hunkapiller M, Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington K, Abu-Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R, Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z, Di Francesco V, Dunn P, Eilbeck K, Evangelista C, Gabrielian AE, Gan W, Ge W, Gong F, Gu Z, Guan P, Heiman TJ, Higgins ME, Ji RR, Ke Z, Ketchum KA, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov GV, Milshina N, Moore HM, Naik AK, Narayan VA, Neelam B, Nusskern D, Rusch DB, Salzberg S, Shao W, Shue B, Sun J, Wang Z, Wang A, Wang X, Wang J, Wei M, Wides R, Xiao C, Yan C et al (2001) The sequence of the human genome. Science 291:1304–1351
  Article PubMed CAS Google Scholar
• Verhaart IE, Aartsma-Rus A (2012) Gene therapy for Duchenne muscular dystrophy. Curr Opin Neurol 25:588–596
  Article PubMed CAS Google Scholar
• Visser ME, Kastelein JJ, Stroes ES (2010) Apolipoprotein B synthesis inhibition: results from clinical trials. Curr Opin Lipidol 21:319–323
  Article PubMed CAS Google Scholar
• Visser ME, Witztum JL, Stroes ES, Kastelein JJ (2012) Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J 33:1451–1458
  Article PubMed CAS Google Scholar
• Xia X, Zhou H, Huang Y, Xu Z (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis 23:578–586
  Article PubMed CAS Google Scholar
• Yueksekdag G, Drechsel M, Rossner M, Schmidt C, Kormann M, Illenyi MC, Rudolph C, Rosenecker J (2010) Repeated siRNA application is a precondition for successful mRNA gammaENaC knockdown in the murine airways. Eur J Pharm Biopharm 75:305–310
  Article PubMed CAS Google Scholar
• Zamore PD, Tuschl T, Sharp PA, Bartel DP (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101:25–33
  Article PubMed CAS Google Scholar
• Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79:514–523
  Article PubMed CAS Google Scholar

Download references